scholarly journals Conventional dose rate spatially-fractionated radiation therapy (SFRT) treatment response and its association with dosimetric parameters – A preclinical study in a Fisher 344 rat model

2020 ◽  
Author(s):  
Judith N. Rivera ◽  
Thomas M. Kierski ◽  
Sandeep K. Kasoji ◽  
Anthony S. Abrantes ◽  
Paul A. Dayton ◽  
...  

AbstractPurposeTo identify key dosimetric parameters that have close associations with tumor treatment response and body weight change in SFRT treatments with a large range of spatial-fractionation scale at dose rates of several Gy/min.MethodsSix study arms using uniform tumor radiation, half-tumor radiation, 2mm beam array radiation, 0.3mm minibeam radiation, and an untreated arm were used. All treatments were delivered on a 320kV x-ray irradiator. Forty-two female Fischer 344 rats with fibrosarcoma tumor allografts were used. Dosimetric parameters studied are peak dose and width, valley dose and width, peak-to-valley-dose-ratio, volumetric average dose, percentage volume directly irradiated, and tumor- and normal-tissue EUD. Animal survival, tumor volume change, and body weight change (indicative of treatment toxicity) are tested for association with the dosimetric parameters using linear regression and Cox Proportional Hazards models.ResultsThe dosimetric parameters most closely associated with tumor response are tumor EUD (R2=0.7923, F-stat=15.26*; z-test=−4.07***), valley/minimum dose (R2=0.7636, F-stat=12.92*; z-test=−4.338***), and percentage tumor directly irradiated (R2=0.7153, F-stat=10.05*; z-test=−3.837***) per the linear regression and Cox Proportional Hazards models, respectively. Tumor response is linearly proportional to valley/minimum doses and tumor EUD. Average dose (R2=0.2745, F-stat=1.514 (no sig.); z-test=−2.811**) and peak dose (R2=0.04472, F-stat=0.6874 (not sig.); z-test=−0.786 (not sig.)) show the weakest associations to tumor response. Only the uniform radiation arm did not gain body weight post-radiation, indicative of treatment toxicity; however, body weight change in general shows weak association with all dosimetric parameters except for valley/min dose (R2=0.3814, F-stat=13.56**), valley width (R2=0.2853, F-stat=8.783**), and peak width (R2=0.2759, F-stat=8.382**).ConclusionsFor a single-fraction SFRT at conventional dose rates, valley, not peak, dose is closely associated with tumor treatment response and thus should be used for treatment prescription. Tumor EUD, valley/min dose, and percentage tumor directly irradiated are the top three dosimetric parameters that exhibited close associations with tumor response.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 103-103 ◽  
Author(s):  
Shiva Shrotriya ◽  
Declan Walsh ◽  
Aynur Aktas ◽  
Bassam N. Estfan

103 Background: Body weight change in adults with solid tumors was examined in outpatients. Objective was to determine if demographics, clinical and biochemical characteristics were associated with change in weight between visit 1 and visit 2. Examine if weight change and related parameters were associated with survival. Methods: Electronic medical records (EMR) from a tertiary cancer center retrospectively reviewed from 2009-2011. Body weight and other clinical parameters on visit 1 - within a year post diagnosis; visit 2 ≥3 weeks after visit 1. Weight change categorized as: weight gain, 0-5%, 5.01-10%, >10%. Ordinal logistic regression and Cox proportional hazards utilized for WL predictors and prognostic factors respectively. Results: N = 5,901; Mean age (±SD): 61 ± 12 years; 82% were Caucasians; 16% African Americans. Common cancers were prostate 19%; breast 15%; lung 15%; head and neck 6%; colorectal 6%; others 12%. Metastatic disease was present in 18%. Bone, brain, lymph nodes – were common metastatic sites. 45% had radiotherapy; 41% chemotherapy. Median weight change from visit 1 to visit 2 = -1 (-48, 66) kgs. Weight loss (WL) in 57% (≤5%: 30%, 5.01-10%: 13%, >10%: 14%). Different primary cancer sites, number of metastatic sites, radiotherapy/chemotherapy/hormonal therapies, older age, body mass index (BMI), and albumin predicted weight change. Median survival in 5.01-10.0% WL= 9.4 months, >10.0% = 5.3 months, and not observed ≤ 5%. Conclusions: 1. Majority lost ≤5% of body weight by visit 2. 2. Esophagus, head and neck, and pancreas (primary) - the greatest risk of WL; prostate – lowest. 3. High BMI predicted greater WL compared to normal or underweight. 4. ≤5% WL had a survival advantage compared to 5.01-10% and >10%. 5. WL remained prognostic for survival after adjusting for other prognostic factors.


2020 ◽  
Vol 3 (1) ◽  
pp. 24-30
Author(s):  
Eun-Sub Lee ◽  
Jung-Min Choi ◽  
Nam-Seok Joo

2008 ◽  
Vol 4 (3) ◽  
pp. e1000045 ◽  
Author(s):  
Carson C. Chow ◽  
Kevin D. Hall

2014 ◽  
Vol 57 (3) ◽  
pp. 317-332 ◽  
Author(s):  
Frederic Nduhirabandi ◽  
Barbara Huisamen ◽  
Hans Strijdom ◽  
Dee Blackhurst ◽  
Amanda Lochner

Sign in / Sign up

Export Citation Format

Share Document